High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes: Results of a 6-year follow-up by Ficociello, Linda H. et al.
High-Normal Serum Uric Acid Increases
Risk of Early Progressive Renal Function
Loss in Type 1 Diabetes
Results of a 6-year follow-up
LINDA H. FICOCIELLO, DSC
1,2
ELIZABETH T. ROSOLOWSKY, MD, MPH
1,3,4
MONIKA A. NIEWCZAS, MD, PHD
1,4
NICHOLAS J. MASELLI, BA
1
JANICE M. WEINBERG, SCD
2
ANN ASCHENGRAU, SCD
2
JOHN H. ECKFELDT, MD, PHD
5
ROBERT C. STANTON, MD
1,4
ANDRZEJ T. GALECKI, MD, PHD
6
ALESSANDRO DORIA, MD, PHD, MPH
1,4
JAMES H. WARRAM, MD, SCD
1
ANDRZEJ S. KROLEWSKI, MD, PHD
1,4
OBJECTIVE — We previously described a cross-sectional association between serum uric
acid and reduced glomerular ﬁltration rate (GFR) in nonproteinuric patients with type 1 diabe-
tes. Here, we prospectively investigated whether baseline uric acid impacts the risk of early
progressive renal function loss (early GFR loss) in these patients.
RESEARCH DESIGN AND METHODS — Patients with elevated urinary albumin ex-
cretion (n  355) were followed for 4–6 years for changes in urinary albumin excretion and
GFR. The changes were estimated by multiple determinations of albumin-to-creatinine ratios
(ACRs) and serum cystatin C (GFRcystatin).
RESULTS — At baseline, the medians (25th–75th percentiles) for uric acid, ACR, and
GFRcystatin values were 4.6 mg/dl (3.8–5.4), 26.2 mg/g (15.1–56.0), and 129 ml/min per 1.73
m
2 (111–145), respectively. During the 6-year follow-up, signiﬁcant association (P  0.0002)
was observed between serum uric acid and development of early GFR loss, deﬁned as
GFRcystatin decline exceeding 3.3% per year. In baseline uric acid concentration categories (in
mg/dl: 3.0, 3.0–3.9, 4.0–4.9, 5.0–5.9, and 6), the risk of early GFR loss increased linearly
(9, 13, 20, 29, and 36%, respectively). This linear increase corresponds to odds ratio 1.4 (95%
CI1.1–1.8)per1mg/dlincreaseofuricacid.Theprogressionandregressionofurinaryalbumin
excretion were not associated with uric acid.
CONCLUSIONS — We found a clear dose-response relation between serum uric acid and
risk of early GFR loss in patients with type 1 diabetes. Clinical trials are warranted to determine
whether uric acid–lowering drugs can halt renal function decline before it becomes clinically
signiﬁcant.
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T
he paradigm of early diabetic ne-
phropathy in type 1 diabetes has
changed during the past few years.
Previously, it focused on urinary leakage
of small amounts of albumin, designated
microalbuminuria, which was believed to
predict progression to overt proteinuria
and ultimately end-stage renal disease
(ESRD)(1).However,recentstudies(2,3)
documentedthatratherthanprogression,
regression to normoalbuminuria is the
fate of microalbuminuria in the majority
of patients. Progression to proteinuria is
the fate in a minority only. At the same
time, the onset of progressive renal func-
tion loss was observed in a subset of these
patients well before the onset of protein-
uria(4).Becausethisdeclineoccurswhile
renal function is still normal, we label it
“early” progressive renal function loss
(earlyGFRloss).Whereasmicroalbumin-
uria may regress, remain stable, or
progress during the course of diabetes,
early GFR loss progresses to chronic kid-
ney disease (CKD) and ESRD (4–6).
Because early GFR loss is detectable
whilerenalfunctionisnormalorelevated,
an opportunity may exist for effective in-
tervention many years before the occur-
renceofmeaningfullossofrenalfunction.
However, our knowledge of early GFR
loss determinants is limited (4). Discov-
ery of these determinants, especially
modiﬁableones,mayenablethedesignof
more effective programs for the preven-
tion of CKD and ESRD.
A body of evidence suggests that ele-
vated serum uric acid may cause kidney
injuryinanimalmodels(7).Also,mount-
ing evidence points to a role of elevated
serum uric acid in the development of
kidneydiseaseinhumans.Incohortstud-
iesofsubjectswithoutdiabetes,hyperuri-
cemia predicted the development of CKD
stage 3 (8) and ESRD (9,10), and in com-
munity-based cohorts moderately ele-
vated serum uric acid concentrations
were associated with the development of
CKDstage3(11,12).Recently,inatype1
diabetic cohort in Denmark, moderately
elevated uric acid concentrations were
found to be associated with risk of pro-
teinuria during an 18-year follow-up
(13). However, changes in renal function
were not examined.
The Second Joslin Study on the Nat-
ural History of Microalbuminuria in Type
1 Diabetes (Second Joslin Study) is a fol-
low-up study designed to determine the
natural history of early diabetic nephrop-
athy in nonproteinuric patients with type
1 diabetes. In baseline data, high-normal
serum uric acid concentration was
strongly associated with reduced glomer-
ular ﬁltration rate (GFR), as estimated by
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Whether elevated serum uric acid pre-
cededorfollowedreducedGFRcouldnot
be determined in that cross-sectional
data. Therefore, we prospectively mea-
sured GFRcystatin during 4–6 years of
follow-up and investigated the associa-
tion between baseline serum uric acid
concentration and changes in renal func-
tion. A secondary aim was to explore the
role of serum uric acid in the progression
and regression of urinary albumin
excretion.
RESEARCH DESIGN AND
METHODS— Thestudyprotocoland
informed consent procedures were ap-
provedbytheCommitteeonHumanSub-
jects of the Joslin Diabetes Center.
This study is a prospective follow-up
study on the impact of baseline levels of
serum uric acid on changes in renal func-
tion and urinary albumin excretion over
the next 4–6 years of follow-up.
Participants included in this report
aremembersoftheSecondJoslinStudy,a
prospective follow-up study described
previously (14). Brieﬂy, any patient aged
18–64 years with type 1 diabetes who
attended the Joslin Clinic during 2003–
2005 and had at least two albumin-to-
creatinine ratios (ACRs) determined
during the 2 preceding years was poten-
tially eligible for enrollment with an entry
examination. Eligibility was restricted
furthertoNewEnglandresidentswithdi-
abetes diagnosed before age 40 years and
whowerecontinuouslytreatedwithinsu-
lin. Exclusion criteria included presence
of proteinuria, ESRD, kidney transplant,
or comorbidity such as HIV, hepatitis C,
or non–diabetes-related kidney disease.
Ninety percent of patients identiﬁed
themselves as white. A total of 667 pa-
tients were examined and enrolled in the
Second Joslin Study.
Previously we found that risk of early
GFR loss was very low in patients with
type 1 diabetes and low normoalbumin-
uria (median ACR 10 mg/g in women
and8mg/ginmen)(4),weexcludedsuch
patients (n  183) from the follow-up
phase of the Second Joslin Study. The re-
maining 484 patients had baseline high
normoalbuminuria (ACR median 8–24
mg/g in women and 10–16 mg/g in men,
n  180) or microalbuminuria (ACR me-
dian25–354mg/ginwomenand17–249
mg/ginmen,n304)andwerefollowed
until the end of 2009 with the aim of ex-
amining and obtaining serum and urine
specimens annually.
For this study, we excluded 35 pa-
tients with CKD stage 3 or higher at base-
line, two patients without baseline uric
acid measurements, 35 patients treated
with diuretics, and 1 treated with allo-
purinol. Of the remaining 411 patients
eligible for follow-up, 355 (86%) had
multiplemeasures(median5)ofserum
cystatin C to estimate GFR and multiple
determinationsofACR(median5)dur-
ing 4 years of follow-up.
Entry examination and
measurements of exposures
At the entry examination, a trained study
recruiter administered a questionnaire on
medical and diabetes history, including
medication usage; obtained blood and
urine samples; and measured seated
blood pressures twice, separated by a
5-minrest.Medicalrecordreviewsupple-
mented questionnaire information as
needed.
Clinical characteristics (A1C, ACR,
and serum cholesterol and HDL) mea-
sured at routine clinic visits during the
preceding 2 years were retrieved from
electroniclaboratoryrecords.Themedian
of repeated determinations within the
2-year interval (including entry examina-
tion) was used as the baseline value. All
other baseline characteristics were mea-
sured at entry examination.
Details of the assay for uric acid have
been published previously (14). Uric acid
was measured using a timed end point
method on a Beckman Coulter Synchron
CX9. Of the patients enrolled in this
study, 262 had follow-up uric acid mea-
surementswithin2yearsofbaselinemea-
surement. The correlation coefﬁcient
(Spearman) between ﬁrst and second
measurements was 0.78. In our lab, the
interassay coefﬁcient of variation for uric
acid was 2%.
Follow-up examination
Participants were followed yearly to mea-
sure GFRcystatin and level of microalbu-
minuria over the next 4–6 years. The
examination and collection of specimens
coincidedwithpatients’routineclinicvis-
its. Patients who stopped coming to the
clinic were examined at their homes.
Measurement of GFRcystatin
Serum cystatin C has been shown to esti-
mate GFR and track GFR changes over
time well in patients with diabetes and
normal or elevated renal function
(4,15,16). In 2009, serum cystatin C was
measured in stored (85 C) baseline and
follow-up samples in the collaborative
studies clinical laboratory at the Univer-
sity of Minnesota using the Dade-
Behring-Siemens BN ProSpec (Siemens
Healthcare Diagnostics, Deerﬁeld, IL).
The method’s interassay laboratory coef-
ﬁcientofvariationis4.7%.GFRcystatin
was estimated from the serum concentra-
tion of cystatin C using a recently im-
provedconversionformula(17)(127.7
CysC
1.17  age
0.13  [0.91 if female,
1.06 if black]) (13).
Measurement of urinary albumin
excretion
The protocol for measuring urinary ACR
in spot urines during prior clinic visits
and during follow-up remained un-
changed as described previously (14).
Deﬁnition of renal outcomes
While our primary outcome is early GFR
loss, the study design allowed simulta-
neous assessment of changes in renal
function and changes in urinary albumin
excretion. The deﬁnition of these out-
comes follows.
Early GFR loss
We calculated individual-speciﬁc slopes
ofGFRcystatinduringfollow-upwithlin-
ear mixed-effects regression (PROC
MIXED, SAS version 9.1; SAS Institute,
Cary, NC). From these slopes, we derived
each individual’s percent change per year
in GFRcystatin. Next, we grouped pa-
tients into 1) those with early GFR loss (if
the loss of GFRcystatin exceeded 3.3%
per year) and 2) those with stable renal
function (if the loss of GFRcystatin was
3.3% or less per year). This criterion, a
loss exceeding than 3.3% per year, was
derived by us previously (4) and corre-
sponds to the 2.5th percentile of the dis-
tribution of GFR slopes in an
independent, similarly aged population
without diabetes (18).
CKD stage 3 or greater
CKD stage 3 is deﬁned as a GFRcystatin
value 60 ml/min per 1.73 m
2. Patients
with CKD stage 3 or greater at baseline
were excluded. If CKD stage 3 developed
during the 4–6 years of follow-up,
the outcome date was that of the ﬁrst
GFRcystatin 60 ml/min per 1.73 m
2.
Change in ACR
To evaluate changes in urinary albumin
excretion for each patient, we divided ob-
servation time into three 2-year intervals.
The median ACR measurement in the
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the baseline value. Similarly, during the
ﬁrst two 2-year intervals after enrollment,
the median ACR measurement in each
was considered the ﬁrst and second fol-
low-up value, respectively. ACR progres-
sion was deﬁned as a doubling of baseline
ACRvalueduringeitheroftheseintervals.
ACR regression was deﬁned as a halving
of baseline ACR value during either
interval.
Statistical methods
All statistical analyses were performed in
SAS version 9.1 (SAS Institute). Compar-
isons between those with early GFR loss
andthosewithstablerenalfunctionatthe
end of follow-up used medians and Wil-
coxon rank sum tests for continuous vari-
ables and percentages and 
2 tests for
categorical variables. The odds of devel-
oping early GFR loss or ACR progression
or regression were estimated with logistic
regression. Characteristics associated
withuricacidorearlyGFRlosswereeval-
uated as potential confounders in multi-
variate models. Characteristics were
retained if they changed the relation be-
tween uric acid and early GFR loss by
10%. Controlling for baseline values of
an exposure of interest is controversial if
the study outcome is change in that same
characteristicovertime(19).Weprovide
results both ways: controlling and not
controlling for baseline values of
GFRcystatin for early GFR loss or ACR
for change in ACR.
Longitudinal measures of log-
transformed GFRcystatin levels were also
analyzed using a linear mixed-effects
model. This model takes into account ir-
regular time measurements and correla-
tion between longitudinal observations.
In building the model, we applied a like-
lihoodratiotesttoﬁxedeffectsofuricacid
and confounders. To account for correla-
tion between longitudinal observations,
two random effects, namely random in-
tercept and random slope for time, were
also included. In addition, the linear
mixed-effects framework allowed deriv-
ing and making inference about the dis-
tribution of subject-speciﬁc slopes (and
subsequently percent changes per year)
for any subject after adjusting for poten-
tial confounders.
RESULTS— At the end of follow-up,
study subjects were divided into two
groups according to the primary out-
come: the presence or absence of early
GFR loss. A loss in GFRcystatin that ex-
ceeded 3.3% per year was classiﬁed as
early GFR loss (n  79), all others (n 
276) were considered to have stable renal
function.
The two groups did not differ with
regard to sex, but patients with early GFR
loss were older at both diabetes diagnosis
andstudyentryandhadalongerduration
of diabetes (Table 1). The two groups did
not differ with regard to A1C or clinical
characteristics associated with insulin re-
sistance, such as insulin dose, BMI, and
serumcholesterol(totalorHDL).Patients
with early GFR loss had signiﬁcantly
lower GFRcystatin, higher urinary ACR,
andahigherprevalenceofmicroalbumin-
uria at baseline. Early GFR loss patients
were also more frequently treated with
renoprotective drugs, although the two
groups had similar systolic and diastolic
blood pressures. Both groups had similar
cigarette-smoking history. Most notably,
those with early GFR loss had signiﬁ-
cantly higher serum uric acid levels than
patients with stable renal function (P 
0.0001).
Table 1 also shows results of follow-
up. The last GFRcystatin in patients with
stable renal function was similar to that at
baseline (124 vs. 131 ml/min per 1.73
m
2), whereas it was signiﬁcantly lower
(86 vs. 115 ml/min per 1.73 m
2) in those
with early GFR loss. Median change per
year in GFRcystatin was 1.8 and
4.4%, respectively. CKD stage 3 devel-
oped in 22 patients, among 19 patients
with early GFR loss and among 3 those
with stable renal function.
The two groups were also compared
with regard to urinary albumin excretion
during the 4-year follow-up. In the sec-
ond follow-up interval, the median ACR
value in the early GFR loss group was sig-
niﬁcantly higher than in the stable renal
function group, as noted in the baseline
interval, and in neither group did the me-
dian values increase by the end of follow-
up. To take into account the baseline
differences in ACR values, follow-up
changes in ACR were expressed as fold
changes from baseline in each interval.
Progression was deﬁned as a doubling of
ACRineitherinterval,andregressionwas
deﬁned as a halving of ACR in either in-
terval. ACR progressed in 34% of case
subjects with early GFR loss compared
with 17% of control subjects with stable
renal function (P  0.001). ACR re-
gressedequallyinthetwogroups(33%of
case and in 37% of control subjects).
To further examine the relation be-
tweenbaselineuricacidanddevelopment
ofrenaloutcomes,weanalyzedtheoccur-
rence of these outcomes according to ﬁve
categories of baseline serum uric acid (in
mg/dl: 3.0, 3–3.9, 4–4.9, 5–5.9, and
6). A clear dose-response relation is ev-
ident between increasing baseline serum
uric acid levels and subsequent occur-
rence of early GFR loss (Fig. 1A). During
the4–6yearsoffollow-up,earlyGFRloss
developed in 9, 13, 20, 29, and 36% of
individuals in the ﬁve categories of in-
creasing serum uric acid, respectively (P
for trend  0.0002).
Similarly, we explored a complemen-
tary outcome to early GFR loss (i.e., de-
velopment of CKD stage 3 [or greater]).
Although CKD stage 3 developed in only
22 patients during follow-up, a strong
dose-response relation between baseline
serum uric acid categories and develop-
ment of CKD stage 3 is evident in Fig. 1B.
In the ﬁve categories of increasing serum
uric acid, 0, 4, 3, 6, and 19% of individ-
uals developed CKD stage 3, respectively
(P for trend  0.0005). The association
between baseline serum uric acid and
progression of ACR (Fig. 1C) was not sig-
niﬁcant for trend (P  0.34). Similarly,
the association between baseline serum
uric acid and regression of ACR (Fig. 1D)
was not signiﬁcant for trend (P  0.65).
Estimates from multivariate logistic
regression of the effect of a 1.0 mg/dl in-
crease in serum uric acid on these renal
outcomesaresummarizedinTable2.The
unadjusted odds ratio of developing early
GFR loss with baseline serum uric acid
change by 1 mg/dl was 1.5 (95% CI 1.3–
1.9), and this estimate was little changed
by adjustment for urinary ACR, sex, and
A1C or even adjustment for baseline
GFRcystatin. This association can be re-
expressed as an individual with a serum
uric acid of 6 mg/dl having twice the risk
of developing early GFR loss as an indi-
vidual with a serum uric acid of 4 mg/dl
(odds ratio per 2 mg/dl change  1.9).
There was no effect measure modiﬁca-
tion (interaction) by sex, A1C, baseline
GFRcystatin, or baseline ACR. Due to the
small number of case subjects, we could
not pursue a fully adjusted model for the
time-to-event analysis of CKD stage 3.
The lack of association between serum
uric acid and progression or regression of
ACR was conﬁrmed by logistic regression
in both the univariate and multivariate
analyses (Table 2).
To further study the association be-
tweenserumuricacidandearlyGFRloss,
we analyzed continuous measures of
changes in GFRcystatin using a linear
Ficociello and Associates
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vious confounders. The interaction be-
tween changes in GFRcystatin over time
and serum uric acid was statistically sig-
niﬁcant (P  0.01). This interaction can
be interpreted in terms of differing ad-
justedaveragepercentchangeperyearfor
each of the ﬁve categories of serum uric
acid presented in Fig. 1. The average per-
cent change for the ﬁve categories, from
lowest to highest serum uric acid, was
0.6,1.4,1.8,2.2,and3.1%per
year, respectively.
CONCLUSIONS — Inthislarge,pro-
spective cohort study of type 1 diabetic
patients without proteinuria, we found
that serum uric acid was a signiﬁcant in-
dependent predictor of the development
ofearlyGFRlossaftercontrollingformul-
tiple confounders. For each 1 mg/dl in-
creaseinserumuricacid,therewasa40%
increase in the odds of developing early
GFR loss (odds ratio  1.4 [95% CI 1.1,
1.8]). This increase in risk was linear
across the entire normal range of serum
uric acid levels. In contrast with these
ﬁndings, we did not ﬁnd any association
between baseline serum uric acid and
progression or regression of urinary albu-
min excretion. Our study is the ﬁrst to
provide prospective evidence of the “un-
coupling” of determinants of early GFR
loss from determinants of changes in uri-
nary albumin excretion, the two cardinal
manifestations of early diabetic nephrop-
athy in type 1 diabetes.
Recently, in a type 1 diabetic cohort
withlongfollow-upinDenmark,elevated
baseline uric acid concentrations were as-
sociatedwiththedevelopmentofprotein-
uria but did not impact risk of
microalbuminuria (13). Since that study
didnotreportmeasuresofchangeinrenal
function we cannot compare results for
our main outcome. Our study aimed to
study renal function changes during early
diabetic nephropathy when patients had
only minimally elevated ACR. With
longer follow-up, we may have obtained
similarresultsastheDanishcohort.How-
ever, as we showed in our recent study
(5), declining renal function begins be-
fore proteinuria develops.
Although our ﬁndings are derived
from an observational study, it is intrigu-
ing to consider that uric acid might play a
pathogenic role in the development of
early GFR loss in type 1 diabetes. This
hypothesis can be tested further in ran-
Table 1—Characteristics of nonproteinuric patients with type 1 diabetes according to whether renal function was stable during 4–6 years of
follow-up or early GFR loss developed
Characteristic* Stable renal function Early GFR loss P value
n 276 79
Baseline characteristics
% men 55 56 0.92
Age at diabetes diagnosis (years) 17  10 20  11 0.02
Duration of diabetes (years) 21  92 4  10 0.02
Age (years) 38  12 44  11 0.0001
A1C (%) 8.2 (7.4–9.1) 8.3 (7.6–9.5) 0.17
Insulin dose (units/kg/day) 0.63 (0.53–0.83) 0.64 (0.48–0.86) 0.83
BMI (kg/m
2) 26 (23–29) 26 (24–32) 0.15
Serum cholesterol (mg/dl) 184 (166–204) 185 (167–204) 0.96
Serum HDL (mg/dl) 54 (46–65) 53 (46–64) 0.74
GFRcystatin (ml/min per 1.73 m
2) 131 (116–147) 115 (93–136) 0.0001
ACR (mg/g) 34.6 (22.2–63.8) 51.6 (29.9–114.9) 0.0001
% with microalbuminuria 56 75 0.003
% with renoprotective treatment 50 68 0.005
Systolic blood pressure (mmHg) 120 (111–128) 122 (114–129) 0.13
Diastolic blood pressure (mmHg) 70 (68–79) 72 (68–77) 0.60
Cigarette smoking
% current 18 13 0.18
% past 24 34
Serum uric acid (mg/dl) 4.5 (3.7–5.3) 5.10 (4.4–5.7) 0.0001
Follow-up characteristics
Duration of follow-up (years) 4.8 (4.1–5.5) 4.9 (3.9–5.7) 0.56
Number of cystatin determinations 5 (4–6) 5 (4–6) 0.33
Number of ACR determinations 5 (4–7) 6 (4–7) 0.58
Last GFRcystatin (ml/min per 1.73 m
2) 124 (109–139) 86 (65–99) By design
Percent change per year in GFRcystatin 1.8 (2.4 to 1.2) 4.4 (5.0 to 3.8) By design
Progressed to CKD stage 3 or greater n (%)	 3 (1) 19 (24) 0.0001
Last ACR (mg/g)† 17.1 (9.8, 42.1) 40.3 (13.8, 128.5) 0.0001
Progression of ACR n (%)	 48 (17) 27 (34) 0.001
Regression of ACR n (%)	 103 (73) 26 33) 0.47
Dataaremedians(25th–75thpercentiles)andPvaluesfromWilcoxonranksumtestforcontinuousvariables(exceptforageatdiabetesdiagnosis,duration,andage,
which are means  SD and t tests) and percents with P values from 
2 test for categorical data. *Values for A1C, serum cholesterol, serum HDL, and ACR were the
medians of all determinations during the 2-year interval ending with the entry examination. †Median of all ACR measurements in the second 2-year follow-up
interval.
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drugs to reduce serum uric acid levels are
available, being commonly used in gout
therapy.Thesedrugsreduceuricacidlev-
els either by inhibiting its synthesis (allo-
purinol and febuxostat) or by increasing
the urinary excretion of uric acid (probe-
necid, benzbromarone, and sulﬁnpyra-
zole) (20,21). Several RCTs have shown
that treatment with allopurinol improves
brachial artery vasodilation in patients
with chronic heart failure (22) and type 2
diabetes (23), but only a handful of stud-
ies, all in individuals without diabetes,
have examined changes in renal function
astheprimaryoutcomes.Oneofthesehas
shown that treatment with allopurinol
can retard the renal function decline
among patients with CKD and hyperuri-
cemia (24). No RCT has been conducted
to investigate the effect of uric acid–
lowering drugs on the prevention of early
renal function loss. However, in a pro-
spective study of 48 hyperuricemic pa-
tients who were given allopurinol for 3
months, uric acid decreased from 8.0 to
5.5 mg/dl, while GFR increased from 79
to 93 ml/min per 1.73 m
2 (25). Impor-
tantly, such improvement in GFR oc-
curred in the absence of a reduction of
proteinuria.
The Second Joslin Study is a well-
characterized, large prospective cohort
study with excellent follow-up over 4–6
years, which allowed us to determine dif-
ferent phenotypes/outcomes of early dia-
betic nephropathy. However, some
perceived and real limitations of this
study should be considered. First, al-
thoughweshowedthatrepeateduricacid
measurements taken up to 2 years apart
were highly correlated (r  0.78), some
exposure misclassiﬁcation may have oc-
curred due to the reliance on a single
baseline uric acid measurement. How-
ever, such nondifferential misclassiﬁca-
tionwouldbiastheresultstowardthenull
hypothesis, making our ﬁndings of asso-
ciationevenmorenotable.Second,wees-
timated renal function from serum
cystatin C concentrations rather than
measuring GFR directly. Although indi-
rect, this method has been shown to esti-
mateGFRwelleveninnormalorelevated
ranges, and multiple measurements of
GFRcystatin over time have been demon-
strated to be a reliable tool to assess
changes of renal function in longitudinal
studies (4,15,16). Importantly, to mini-
mize spurious variation in the determina-
tion of GFRcystatin changes over time, all
serum cystatin C measurements (n 
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Figure1—Risksduring4–6yearsfollow-upofearlyGFRloss(A),CKDstage3(B),progression
of ACR (C), or regression of ACR according to baseline concentration of serum uric acid (D).
Baseline serum uric acid values (mg/dl) were 3.0 for 23 patients, between 3.0 and 3.9 for 78
patients, between 4.0 and 4.9 for 118 patients, between 5.0 and 5.9 for 96 patients, and 6.0 for
53 patients. Median uric acid concentration in the cohort was 4.6 mg/dl. A: Test for trend in risk
of early GFR loss with baseline serum uric acid category was signiﬁcant, P  0.0002. B: Test for
trendinriskofCKDstage3withbaselineserumuricacidcategorysigniﬁcant,P0.0005.C:Test
for trend in risk of progression of ACR with baseline uric acid category was not statistically
signiﬁcant,P0.34.D:TestfortrendinriskofregressionofACRwithbaselineuricacidcategory
was not statistically signiﬁcant, P  0.65.
Ficociello and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 13411,871) were carried out in 2009, in the
same laboratory and using the same re-
agents.Furthermore,tocalculateindivid-
ual GFRcystatin slopes, we utilized
appropriate methods of longitudinal
analysis (i.e., linear mixed-effects model),
taking into account irregular time mea-
surementsandcorrelationbetweenlongi-
tudinal observations. Finally, since our
studyisanobservationalone,anyconclu-
sion about a causal relationship between
serum uric acid and the development of
early GFR loss in type 1 diabetes should
be considered as tentative. This hypothe-
sis will have to be tested by adequately
powered RCTs evaluating the effect of
uricacid–loweringdrugsonthedeclineof
renalfunctionspeciﬁcallyamongindivid-
uals with diabetes.
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